Liquidia (LQDA) Stock Analysis

What Liquidia does

Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating on the development, production, and market introduction of various treatments aimed at fulfilling critical patient requirements throughout the United States. A key asset in its developmental portfolio is YUTREPIA, an innovative inhaled dry powder version of treprostinil, intended for managing pulmonary arterial hypertension. Beyond its pipeline, the company also distributes a generic treprostinil injection within the U.S. market. Founded in 2004, Liquidia Corporation's main office is located in Morrisville, North Carolina.

Key metrics

ETFs linked to LQDA

Broad-market and Healthcare sector ETFs an investor holding Liquidia is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how LQDA fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Liquidia?

Liquidia trades under the ticker LQDA on NASDAQ.

Which exchange is LQDA listed on?

LQDA is listed on NASDAQ.

What sector does Liquidia operate in?

Liquidia is classified in the Healthcare sector (Medical - Pharmaceuticals industry).

How can PortView help analyze LQDA in a portfolio?

PortView shows LQDA's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.